I agree that this site is using cookies. You can find further informations here.
X
E. Nagai, Shigenori
167  results:
Search for persons X
?
1

Real-world progression-free survival and overall survival o..:

Yoshinami, Tetsuhiro ; Nagai, Shigenori E. ; Hattori, Masaya...
Breast Cancer.  31 (2024)  4 - p. 621-632 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Eribulin-based neoadjuvant chemotherapy for triple-negative..:

Masuda, Norikazu ; Bando, Hiroko ; Yamanaka, Takashi...
Breast Cancer Research and Treatment.  188 (2021)  1 - p. 117-131 , 2021
Link: https://doi.org/10.1007/..
 
?
3

Deregulation of protein phosphatase 2A inhibitor SET is ass..:

Tozuka, Katsunori ; Wongsirisin, Pattama ; Nagai, Shigenori E....
Scientific Reports.  11 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
4

Correction to: The Japanese Breast Cancer Society Clinical ..:

Shimoi, Tatsunori ; Nagai, Shigenori E. ; Yoshinami, Tetsuhiro...
Breast Cancer.  28 (2021)  4 - p. 985-986 , 2021
Link: https://doi.org/10.1007/..
 
?
5

The efficacy and safety of pertuzumab plus trastuzumab and ..:

Takahashi, Masato ; Ohtani, Shoichiro ; Nagai, Shigenori E....
Breast Cancer Research and Treatment.  185 (2020)  1 - p. 125-134 , 2020
Link: https://doi.org/10.1007/..
 
?
6

The Japanese Breast Cancer Society Clinical Practice Guidel..:

Shimoi, Tatsunori ; Nagai, Shigenori E. ; Yoshinami, Tetsuhiro...
Breast Cancer.  27 (2020)  3 - p. 322-331 , 2020
Link: https://doi.org/10.1007/..
 
?
7

Dose-dense adjuvant chemotherapy: a systematic review and m..:

Yoshinami, Tetsuhiro ; Koizumi, Kei ; Nagai, Shigenori E...
Breast Cancer.  27 (2020)  3 - p. 334-339 , 2020
Link: https://doi.org/10.1007/..
 
?
8

A multi-national, randomised, open-label, parallel, phase I..:

Fujiwara, Yasuhiro ; Mukai, Hirofumi ; Saeki, Toshiaki...
British Journal of Cancer.  120 (2019)  5 - p. 475-480 , 2019
Link: https://doi.org/10.1038/..
 
?
9

TS-1 add-on therapy in Japanese patients with triple-negati..:

Inoue, Kenichi ; Nagai, Shigenori E. ; Saito, Tsuyoshi...
Investigational New Drugs.  38 (2019)  1 - p. 140-147 , 2019
Link: https://doi.org/10.1007/..
 
?
10

Multicenter Observational Study of Fulvestrant 500 mg in Po..:

Kimizuka, Kei ; Inoue, Kenichi ; E. Nagai, Shigenori...
Journal of Nippon Medical School.  86 (2019)  3 - p. 165-171 , 2019
Link: https://doi.org/10.1272/..
 
?
11

A Real-World Retrospective Cohort Study of Combined Therapy..:

Yamada, Hirofumi ; Inoue, Kenichi ; Nagai, Shigenori E....
Journal of Nippon Medical School.  84 (2017)  5 - p. 215-223 , 2017
Link: https://doi.org/10.1272/..
 
?
12

RESILIENCE: Phase III Randomized, Double-Blind Trial Compar..:

Baselga, José ; Zamagni, Claudio ; Gómez, Patricia...
Clinical Breast Cancer.  17 (2017)  8 - p. 585-594.e4 , 2017
Link: https://doi.org/10.1016/..
 
?
13

Eribulin-based neoadjuvant chemotherapy for triple-negative..:

Masuda, Norikazu ; 坂東, 裕子 ; バンドウ, ヒロコ...
33763789.  , 2021
Link: https://tsukuba.repo.nii..
 
?
14

Deregulation of protein phosphatase 2A inhibitor SET is ass..:

Tozuka, Katsunori ; Wongsirisin, Pattama ; Nagai, Shigenori E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270961/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
15

Correction to: The Japanese Breast Cancer Society Clinical ..:

Shimoi, Tatsunori ; Nagai, Shigenori E ; Yoshinami, Tetsuhiro...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213656/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
1-15